Drug (mg/kg) | Dose | Drug Class | Change in Swimming | References |
---|---|---|---|---|
Desipramine | 5 | Tricyclic | Significant increase | Pucilowski and Overstreet, 1993 |
Desipramine | 5 | Tricyclic | Significant increase | Schiller et al., 1992 |
Desipramine | 5 | Tricyclic | Significant increase | Zangen et al., 2001 |
Sertraline | 5.7 | SSRI | Significant increase | Pucilowski and Overstreet, 1993 |
Imipramine | 15 | Tricyclic | Significant increase | Schiller et al., 1992 |
DFP | 1 | Anticholinesterase | No Change | Schiller et al., 1992 |
SSR125543 | 3, 30 | CRF1 antagonist | Significant increase | Overstreet and Griebel, 2004a |
SSR58611A | 1, 3 | β2 NA agonist | Significant increase | Overstreet et al., 2008a |
Nemifitide | 0.3 | Analog of MIF | Significant increase | Overstreet et al., 2004aa |
Amphetamine | 2 | Stimulant | No change | Overstreet et al., 1995 |
Scopolamine | 2 | Anticholinergic agent | No change | Overstreet et al., 1995 |
SSR149415 | 10, 30 | V1b antagonist | Significant increase | Overstreet and Griebel, 2005 |
CP154,526 | 10 × 2 | CRF1 antagonist | Significant increase | Overstreet et al., 2004ba |
Citalopram | 5, 10 | SSRI | Significant increase | Overstreet et al., 2004ba |
Saredutant | 1, 10 | NK2 antagonist | Significant increase | Overstreet et al., 2010aa |
Paroxetine | 7.5 | SSRI significant | Increase | Mork et al., 2011 |
Paroxetine | 7.5 | SSRI | Significant increase | Zangen et al., 2001 |
Ondansetron | 1, 10 | 5-HT3 antagonist | Significant increase | Mork et al., 2011 |
Lu AA33810 | 3, 10 | NPY Y5 antagonist | Significant increase | Walker et al., 2009 |
S 20304 | 1, 20 | Melatonin agonist | Significant increase | Overstreet et al., 1998a |
S 20928 | 1, 10 | Melatonin antagonist | No change | Overstreet et al., 1998a |
Inositol | 1200 | Precursor to inositol | Significant increase | Einat et al., 2002 |
Nicotine | 0.4 | Nicotine agonist | Significant increase | Tizabi et al., 1999 |
NGF | Many | Trophic factor | Significant increase | Overstreet et al., 2010b |
CRF1, corticotropin-releasing factor 1; MIF, melanocyte inhibiting factor; NGF, nerve growth factor; NK2, neurokinin 2; SSRI, selective serotonin reuptake inhibitor; V1b, vasopressin V1b receptor; SSR125543, 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine; SSR58611A, amibegron (ethyl ([(7S)-7-([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy)acetate); SSR149415, nelivaptan ((2S,4R)-1-[(3R)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxo-indolin-3-yl]-4-hydroxy-N,N-dimethyl-pyrrolidine-2-carboxamide); CP154526, N-butyl-N-ethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[3,2-e]pyrimidin-4-amine; Lu AA33810, N-[(trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl)methyl]methanesulfonamide; S 20304, N-(2)7-methoxy-1-naphthyl)ethyl)cyclopropanecarboximide; S 20928, N-(2-(1-naphthyl)ethyl)cyclobutanecarboximide.
↵a These studies included a tricyclic and/or an SSRI as a positive control, and the study drugs significantly increased swim test behavior (reduced immobility).